Barclays raised its price target for Elevance Health from USD 457 to USD 469 on October 7, 2026, maintaining an Overweight rating. This bullish action occurred ahead of the company's scheduled third-quarter earnings report on October 21, 2026, which analysts are closely watching following a strong second quarter. Elevance Health reported robust second-quarter 2026 financials with revenue reaching USD 49.83 billion and adjusted earnings per share of USD 7.45. This performance significantly beat the consensus estimate of USD 6.21 for EPS, demonstrating strong execution against market expectations. The company is expanding its Medicare Advantage portfolio for coverage starting January 1, 2027, including new Dual Eligible and Chronic Condition Special Needs Plans. However, recent challenges persist as Cantor Fitzgerald maintained a lower USD 450 target following Elevance's drop in 2027 Medicare Stars rating to 47 percent from 54 percent in the prior year.